Cargando…

Validation of prognostic scores for survival in cancer patients beyond first-line therapy

BACKGROUND: We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment. METHODS: We previously described two models with good prognostic value based on a combination of Performance Status (PS) and either lactat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trédan, Olivier, Ray-Coquard, Isabelle, Chvetzoff, Gisèle, Rebattu, Paul, Bajard, Agathe, Chabaud, Sylvie, Pérol, David, Saba, Chadi, Quiblier, Florent, Blay, Jean-Yves, Bachelot, Thomas
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063819/ https://www.ncbi.nlm.nih.gov/pubmed/21406082 http://dx.doi.org/10.1186/1471-2407-11-95

Ejemplares similares

Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
por: Belbaraka, Rhizlane, et al.
Publicado: (2010)

Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients
por: Heudel, Pierre, et al.
Publicado: (2022)

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients
por: Manuel, Manuarii, et al.
Publicado: (2012)

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial
por: Pérol, David, et al.
Publicado: (2012)

A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2002)

Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
por: de Bernardi, Axel, et al.
Publicado: (2022)

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR
por: Assaad, Souad, et al.
Publicado: (2020)

Beyond the map: evidencing the spatial dimension of health inequalities
por: Yohan, Fayet, et al.
Publicado: (2020)

Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer
por: Cassier, Philippe A, et al.
Publicado: (2011)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Correction to: Beyond the map: evidencing the spatial dimension of health inequalities
por: Fayet, Yohan, et al.
Publicado: (2021)

Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival
por: Rochefort, Pauline, et al.
Publicado: (2017)

Molecular Mechanisms of Kaposi Sarcoma Development
por: Karabajakian, Andy, et al.
Publicado: (2022)

Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
por: Bonnet, Elise, et al.
Publicado: (2022)

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2003)

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value
por: Jiang, Xiaojun, et al.
Publicado: (2015)

Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
por: Mery, Benoîte, et al.
Publicado: (2023)

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
por: Verronèse, E., et al.
Publicado: (2015)

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
por: Ménétrier-Caux, Christine, et al.
Publicado: (2019)

Risk of death of patients with cancer presenting with severe symptoms of infection, with or without documented COVID-19: In reply to van Dam et al.
por: Assaad, Souad, et al.
Publicado: (2020)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
por: Cassier, Philippe A., et al.
Publicado: (2021)

A candidate molecular signature associated with tamoxifen failure in primary breast cancer
por: Vendrell, Julie A, et al.
Publicado: (2008)

New developments in treatment of ovarian carcinoma: focus on trabectedin
por: Cassier, Philippe A, et al.
Publicado: (2010)

Geographical Accessibility of the Sarcoma Referral Networks in France. Intermediate Results from the IGéAS Research Program
por: Fayet, Yohan, et al.
Publicado: (2018)

A methodological framework for drug development in rare diseases
por: Nony, Patrice, et al.
Publicado: (2014)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
por: Ray-Coquard, I, et al.
Publicado: (2001)

A Personalized Physical Activity Program With Activity Trackers and a Mobile Phone App for Patients With Metastatic Breast Cancer: Protocol for a Single-Arm Feasibility Trial
por: Delrieu, Lidia, et al.
Publicado: (2018)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
por: Trédan, Olivier, et al.
Publicado: (2023)

Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
por: Arnaud-Coffin, Patrick, et al.
Publicado: (2020)

Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience
por: Levard, Alice, et al.
Publicado: (2013)

Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring.
por: Blay, J. Y., et al.
Publicado: (1993)

Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study
por: Delrieu, Lidia, et al.
Publicado: (2020)

Systematic Screening for Occupational Exposures in Lung Cancer Patients: A Prospective French Cohort
por: Pérol, Olivia, et al.
Publicado: (2018)

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
por: Ray-Coquard, I, et al.
Publicado: (2003)

Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer
por: Delrieu, Lidia, et al.
Publicado: (2021)

Activation of rapid oestrogen signalling in aggressive human breast cancers
por: Poulard, Coralie, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_um9p0q9kgcv9mdj0q484tgkek1